News
Swain SM, Miles D, Kim SB, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, ...
In a large Chinese trial presented at the American Society of Clinical Oncology annual meeting, neoadjuvant therapy with a taxane, trastuzumab (Herceptin), and pertuzumab (Perjeta) in combination ...
Rates of HER2 expression are examined and trastuzumab is tested in combination with paclitaxel and carboplatin in patients with resistant advanced ovarian cancer.
June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and patient well-being.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results